Roche's Gazyva Gives Leukemia Patients Extra Year Over Rituxan - Businessweek

[INCIID News Feed]

<img alt="" height="1" width="1" />
Roche&#39;s Gazyva Gives Leukemia Patients Extra Year Over Rituxan
Businessweek
Roche Holding AG (ROG)&#39;s newly approved medicine Gazyva helped patients with chronic lymphocytic leukemia live almost a year longer without their disease progressing than its top-seller, Rituxan, in a clinical trial. Patients taking Gazyva along with the ...
New Roche leukemia drug shows clear advantage over Rituxan: studyGlobalPost
Genentech&#39;s Gazyva Helped People with One of the Most Common Forms of ...EON: Enhanced Online News (press release)

all 4 news articles &raquo;


More...